Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 114

1.

Rosiglitazone and the case for safety over certainty.

Juurlink DN.

JAMA. 2010 Jul 28;304(4):469-71. doi: 10.1001/jama.2010.954. Epub 2010 Jun 28. No abstract available.

PMID:
20584879
2.

Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone.

Graham DJ, Ouellet-Hellstrom R, MaCurdy TE, Ali F, Sholley C, Worrall C, Kelman JA.

JAMA. 2010 Jul 28;304(4):411-8. doi: 10.1001/jama.2010.920. Epub 2010 Jun 28.

PMID:
20584880
3.

The rosiglitazone meta-analysis.

McCullough PA, Lepor NE.

Rev Cardiovasc Med. 2007 Spring;8(2):123-6. Review. No abstract available. Erratum in: Rev Cardiovasc Med. 2007 Summer;8(3):174.

PMID:
17603430
4.

Rosiglitazone and cardiovascular disease: an epidemiologist's perspective.

McGuire DK.

Diab Vasc Dis Res. 2007 Jun;4(2):77-9. No abstract available.

PMID:
17654438
5.

Rosiglitazone and cardiovascular disease: a diabetologist's perspective.

Grant PJ.

Diab Vasc Dis Res. 2007 Jun;4(2):75-6. No abstract available.

PMID:
17654437
6.

The safety of rosiglitazone in the treatment of type 2 diabetes.

Singh S, Loke YK.

Expert Opin Drug Saf. 2008 Sep;7(5):579-85. doi: 10.1517/14740338.7.5.579 . Review.

PMID:
18759710
7.

Cardiac safety profile of rosiglitazone: a comprehensive meta-analysis of randomized clinical trials.

Mannucci E, Monami M, Di Bari M, Lamanna C, Gori F, Gensini GF, Marchionni N.

Int J Cardiol. 2010 Aug 20;143(2):135-40. doi: 10.1016/j.ijcard.2009.01.064. Epub 2009 Mar 27.

PMID:
19328563
8.

Rosiglitazone or pioglitazone in type 2 diabetes?

de Vries CS, Russell-Jones DL.

BMJ. 2009 Aug 18;339:b3076. doi: 10.1136/bmj.b3076. No abstract available.

PMID:
19690344
9.

Rosiglitazone and heart failure: the controversy and clinical implications.

Virk IS, Ruby RS, Tepper D.

Congest Heart Fail. 2007 Sep-Oct;13(5):293-5.

10.

Rosiglitazone and cardiovascular risk.

Mannucci E, Monami M, Marchionni N.

N Engl J Med. 2007 Aug 30;357(9):938; author reply 939-40. No abstract available.

PMID:
17806136
11.

Rosiglitazone and cardiovascular disease: a cardiologist's perspective.

Marx N.

Diab Vasc Dis Res. 2007 Jun;4(2):80-1. No abstract available.

PMID:
17654439
12.

The record on rosiglitazone and the risk of myocardial infarction.

Psaty BM, Furberg CD.

N Engl J Med. 2007 Jul 5;357(1):67-9. Epub 2007 Jun 5. No abstract available.

13.

Rosiglitazone and cardiovascular risk.

Diamond GA, Kaul S.

N Engl J Med. 2007 Aug 30;357(9):938-9; author reply 939-40. No abstract available.

PMID:
17806135
14.

Comparative cardiovascular effects of thiazolidinediones: systematic review and meta-analysis of observational studies.

Loke YK, Kwok CS, Singh S.

BMJ. 2011 Mar 17;342:d1309. doi: 10.1136/bmj.d1309. Review.

15.

[Doubts as to the cardiovascular safety of rosiglitazone].

Wolffenbuttel BH.

Ned Tijdschr Geneeskd. 2007 Oct 6;151(40):2236-7; author reply 2237. Dutch. No abstract available.

PMID:
17969577
16.

Rosiglitazone: a thunderstorm from scarce and fragile data.

Mulrow CD, Cornell J, Localio AR.

Ann Intern Med. 2007 Oct 16;147(8):585-7. No abstract available.

PMID:
17938398
17.

Panel recommends easing restrictions on rosiglitazone despite concerns about cardiovascular safety.

Mitka M.

JAMA. 2013 Jul 17;310(3):246-7. doi: 10.1001/jama.2013.8141. No abstract available.

PMID:
23860970
18.

Rosiglitazone and cardiovascular risk.

Psaty BM, Furberg CD.

N Engl J Med. 2007 Jun 14;356(24):2522-4. Epub 2007 May 21. No abstract available.

19.

Type 2 diabetes, thiazolidinediones, and cardiovascular risk.

Taylor C, Hobbs FD.

Br J Gen Pract. 2009 Jul;59(564):520-4. doi: 10.3399/bjgp09X453440.

20.

Incidence of cardiovascular events in which 2 thiazolidinediones are used as add-on treatments for type 2 diabetes mellitus in a Taiwanese population.

Wang CC, Chen WL, Kao TW, Chang YW, Loh CH, Chou CC.

Clin Ther. 2011 Dec;33(12):1904-13. doi: 10.1016/j.clinthera.2011.10.025. Epub 2011 Nov 25. Erratum in: Clin Ther. 2012 Feb;34(2):508. Chou, Chih-Chieh [corrected to Chou, Chin-Chieh].

PMID:
22118894

Supplemental Content

Support Center